Compare Prologis Inc (PLD) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prologis Inc vs Tango Therapeutics Inc. — how do they compare? Prologis Inc trades at $130.45 (market cap $126.92B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Prologis Inc is far larger — about 33.8× Tango Therapeutics Inc.'s market cap, and Prologis Inc pays a 3.2% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prologis Inc for 102 Days and Tango Therapeutics Inc. for 0 Days on average.
| PLD | TNGX | |
|---|---|---|
Market Cap | $126.92B | $3.75B |
Volume | 4,456,134 | 9,619,106 |
Sector | Real Estate | Health |
52-Week High | $149.96 | $32.90 |
52-Week Low | $121.17 | $7.50 |
Typical Hold Time | 102 Days | 0 Days |
Enterprise Value | $161.66B | $2.77B |
Dividend Yield | 3.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prologis (PLD) trades at $130.53, down 1.46% on the day, with strong fundamentals including 45.79% net income margin and consistent earnings beats. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages, trading near support at $130. Recent news highlights leasing growth and data center expansion opportunities, while institutional buying continues.
Outlook remains positive with 61.9% analyst buy ratings and $155.15 consensus target offering 19% upside. Key risks include elevated valuation multiples (P/E 29.74) and rising debt-to-asset ratio (37.2% in 2025). The company's logistics real estate portfolio benefits from e-commerce and data center demand trends.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
